Simple Insulin Measures Sort New-Onset Type 2 Diabetes into Four Subtypes

Researchers analyzing 21,340 people newly diagnosed with type 2 diabetes report that a classification built from two insulin-based measures splits patients into four subtypes with clearly different metabolic profiles and complication burdens. The study, published in Advances in Therapy, used the homeostatic model assessments of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β), computed for each untreated patient at diagnosis. Using the overall medians of these two indices as cut points, the team assigned every participant to one of four groups: high resistance with low secretion, high resistance with high secretion, low resistance with low secretion, and low resistance with high secretion. All between-group comparisons across clinical and metabolic variables reached a p value below 0.001, underscoring how sharply these physiologically defined clusters diverge even among people who have only just received their diagnosis.

The largest burden fell on the high-resistance, low-secretion group, which comprised 2,743 patients. This subtype showed the lowest disposition index, a composite measure reflecting how well beta-cell secretion compensates for the degree of insulin resistance, together with the worst metabolic indicators and the highest cross-sectional risk of complications. At the opposite end, the low-resistance, high-secretion group of 2,735 patients displayed the highest disposition index and the mildest metabolic abnormalities of the cohort. Between these poles sat two intermediate phenotypes. The high-resistance, high-secretion group, the largest at 7,935 patients, exhibited markedly elevated insulin levels and a moderate disposition index, a pattern the authors describe as typical of metabolic syndrome. The low-resistance, low-secretion group, with 7,927 patients, showed severe insulin secretory defects: despite relatively good insulin sensitivity, their poor secretion left them with only a moderate disposition index.

The findings address a long-standing challenge in diabetology. Type 2 diabetes arises from multiple pathophysiological mechanisms, and the resulting clinical heterogeneity means that patients who share the same diagnosis can differ substantially in underlying biology and in the complications they face. This analysis focused exclusively on patients who had just been diagnosed and were not yet receiving treatment, providing a baseline snapshot of islet function before therapy could alter the metabolic picture. Because the two sorting indices were computed at a single baseline assessment, the classification rests on the physiological state present at diagnosis rather than on measures taken after treatment had begun.

Because the complication assessment in this report is cross-sectional, the results describe differences in complication risk present at the time of diagnosis rather than outcomes tracked forward in time. The published abstract indicates that the groups were compared in terms of prognosis, islet function, metabolic markers, and demographics, but the headline result rests on baseline contrasts: the four subtypes differed significantly in insulin levels, insulin sensitivity, beta-cell secretory capacity, disposition index, and complication prevalence. The high-resistance, low-secretion phenotype stands out as the group in which impaired sensitivity and failing secretion compound each other, producing the poorest metabolic profile, while the low-resistance, high-secretion phenotype retains the greatest functional reserve.

The authors conclude that this two-variable classification can effectively identify type 2 diabetes subtypes with distinct pathophysiological mechanisms and clinical prognoses, and they position it as a useful framework for precision medicine in the disease. For now, the study establishes that a stratification based on HOMA-IR and HOMA-β, applied to a large sample of treatment-naive patients at diagnosis, reveals clinically meaningful heterogeneity that a single diagnosis label conceals.

Subject of Research: Islet Function Phenotyping-Based Heterogeneity in New-Onset Type 2 Diabetes: Clinical Importance and Baseline Metabolic Phenotype in a Large-Sample Cohort

Article Title: Islet Function Phenotyping-Based Heterogeneity in New-Onset Type 2 Diabetes: Clinical Importance and Baseline Metabolic Phenotype in a Large-Sample Cohort

Article References: Guo, J., Song, M., Zhou, Y., Wu, X., & Pan, C. (2026). Islet Function Phenotyping-Based Heterogeneity in New-Onset Type 2 Diabetes: Clinical Importance and Baseline Metabolic Phenotype in a Large-Sample Cohort. Advances in Therapy. https://doi.org/10.1007/s12325-026-03821-y

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03821-y

Keywords: Islet, Function, Phenotyping-Based, Heterogeneity, New-Onset, Type, Diabetes, Clinical, Importance, Baseline, Metabolic, Phenotype